These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20423992)

  • 1. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth.
    Grimshaw KM; Hunter LJ; Yap TA; Heaton SP; Walton MI; Woodhead SJ; Fazal L; Reule M; Davies TG; Seavers LC; Lock V; Lyons JF; Thompson NT; Workman P; Garrett MD
    Mol Cancer Ther; 2010 May; 9(5):1100-10. PubMed ID: 20423992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
    Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
    PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930.
    Yap TA; Walton MI; Hunter LJ; Valenti M; de Haven Brandon A; Eve PD; Ruddle R; Heaton SP; Henley A; Pickard L; Vijayaraghavan G; Caldwell JJ; Thompson NT; Aherne W; Raynaud FI; Eccles SA; Workman P; Collins I; Garrett MD
    Mol Cancer Ther; 2011 Feb; 10(2):360-71. PubMed ID: 21191045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.
    Yang F; Deng R; Qian XJ; Chang SH; Wu XQ; Qin J; Feng GK; Ding K; Zhu XF
    Cell Death Dis; 2014 Mar; 5(3):e1114. PubMed ID: 24625973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and evaluation of a series of pyrazolopyrimidines as p70S6K inhibitors.
    Bussenius J; Anand NK; Blazey CM; Bowles OJ; Bannen LC; Chan DS; Chen B; Co EW; Costanzo S; DeFina SC; Dubenko L; Engst S; Franzini M; Huang P; Jammalamadaka V; Khoury RG; Kim MH; Klein RR; Laird D; Le DT; Mac MB; Matthews DJ; Markby D; Miller N; Nuss JM; Parks JJ; Tsang TH; Tsuhako AL; Wang Y; Xu W; Rice KD
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2283-6. PubMed ID: 22342124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks.
    Chuu CP; Lin HP; Ciaccio MF; Kokontis JM; Hause RJ; Hiipakka RA; Liao S; Jones RB
    Cancer Prev Res (Phila); 2012 May; 5(5):788-97. PubMed ID: 22562408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer.
    Azaro A; Rodon J; Calles A; Braña I; Hidalgo M; Lopez-Casas PP; Munoz M; Westwood P; Miller J; Moser BA; Ohnmacht U; Bumgardner W; Benhadji KA; Calvo E
    Invest New Drugs; 2015 Jun; 33(3):710-9. PubMed ID: 25902900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
    Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
    Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of the activity of the PI3K/mTOR inhibitor XL765 (SAR245409) in tumor models with diverse genetic alterations affecting the PI3K pathway.
    Yu P; Laird AD; Du X; Wu J; Won KA; Yamaguchi K; Hsu PP; Qian F; Jaeger CT; Zhang W; Buhr CA; Shen P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Lee M; Bentzien F; Lam ST; Dale S; Matthews DJ; Lamb P; Foster P
    Mol Cancer Ther; 2014 May; 13(5):1078-91. PubMed ID: 24634413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity.
    Yap TA; Walton MI; Grimshaw KM; Te Poele RH; Eve PD; Valenti MR; de Haven Brandon AK; Martins V; Zetterlund A; Heaton SP; Heinzmann K; Jones PS; Feltell RE; Reule M; Woodhead SJ; Davies TG; Lyons JF; Raynaud FI; Eccles SA; Workman P; Thompson NT; Garrett MD
    Clin Cancer Res; 2012 Jul; 18(14):3912-23. PubMed ID: 22781553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational pharmacokinetic-pharmacodynamic modeling from nonclinical to clinical development: a case study of anticancer drug, crizotinib.
    Yamazaki S
    AAPS J; 2013 Apr; 15(2):354-66. PubMed ID: 23250669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
    Foster P; Yamaguchi K; Hsu PP; Qian F; Du X; Wu J; Won KA; Yu P; Jaeger CT; Zhang W; Marlowe CK; Keast P; Abulafia W; Chen J; Young J; Plonowski A; Yakes FM; Chu F; Engell K; Bentzien F; Lam ST; Dale S; Yturralde O; Matthews DJ; Lamb P; Laird AD
    Mol Cancer Ther; 2015 Apr; 14(4):931-40. PubMed ID: 25637314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.
    Maira SM; Pecchi S; Huang A; Burger M; Knapp M; Sterker D; Schnell C; Guthy D; Nagel T; Wiesmann M; Brachmann S; Fritsch C; Dorsch M; Chène P; Shoemaker K; De Pover A; Menezes D; Martiny-Baron G; Fabbro D; Wilson CJ; Schlegel R; Hofmann F; García-Echeverría C; Sellers WR; Voliva CF
    Mol Cancer Ther; 2012 Feb; 11(2):317-28. PubMed ID: 22188813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT13148, a first-in-class multi-AGC kinase inhibitor, potently inhibits gastric cancer cells both in vitro and in vivo.
    Xi Y; Niu J; Shen Y; Li D; Peng X; Wu X
    Biochem Biophys Res Commun; 2016 Sep; 478(1):330-336. PubMed ID: 26828267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
    Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
    Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor.
    Dumble M; Crouthamel MC; Zhang SY; Schaber M; Levy D; Robell K; Liu Q; Figueroa DJ; Minthorn EA; Seefeld MA; Rouse MB; Rabindran SK; Heerding DA; Kumar R
    PLoS One; 2014; 9(6):e100880. PubMed ID: 24978597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways.
    Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X
    PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.